Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
April 22, 2024 07:00 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team
April 09, 2024 07:00 ET
|
Plus Therapeutics Inc.
The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic commitments but will greatly contribute to Plus’...
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
March 27, 2024 08:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
March 25, 2024 08:00 ET
|
Plus Therapeutics Inc.
Plus’ CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and melanoma cancer cells in the leptomeninges CSF-01 testing is used as an...
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
March 11, 2024 07:00 ET
|
Plus Therapeutics Inc.
A total of 18 patients have been dosed in the trial to date Company anticipates moving into Cohort 6 in Q2 2024 following standard safety review AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) --...
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
March 05, 2024 16:05 ET
|
Plus Therapeutics Inc.
Began enrollment of the 5th of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase 1 dose escalation trial with rhenium (186Re) obisbemeda for leptomeningeal metastases (LM) Reached...
Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024
February 27, 2024 08:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Updates Financial and Cash Guidance for 2024
December 18, 2023 07:00 ET
|
Plus Therapeutics Inc.
Plus Receives $3.3M in grant revenue in Q4 2023 Forecasts additional $6.9M of grant revenue for 2024 Enters into debt restructuring deal with Pershing Capital to reduce 2024 cash burn by $3.7M ...
Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses
December 12, 2023 08:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe
November 29, 2023 08:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...